Bespak ready to break with the past, maintains growth plans despite Exubera hitch
This article was originally published in Clinica
A good financial performance in the year 2006-07 for UK drug delivery and anaesthesia device specialist Bespak was tempered marginally by its board's comments that the current year will be "broadly flat". This, it said, would be as a result of declining sales of valves for ozone-depleting CFC formulations in the US and a fall in production volumes of the Exubera insulin inhaler device, following slower-than-expected uptake of the device.
You may also be interested in...
Medical products that do not fully comply with Canadian requirements but are manufactured according to comparable standards are being allowed into the country to deal with COVID-19-related shortages.
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.